Actuate Therapeutics, Inc. Common stock ACTU
0.33 USD 0.00 (+0.55%)
At closeNov 6, 2026, 4:00 PM EST
0.32 -0.01 -1.98%
After hours · Nov 6, 4:00 PM ET
0.3006 Day range 0.3499
0.327 52-week range 7.63
- YTD
- -94.63%
- 1 year
- -94.72%
News
benzinga.com Actuate Therapeutics To Present New Clinical Data Of Oral Elraglusib At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat
globenewswire.com Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026 - Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model - Phase 1/2…
globenewswire.com Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Nasdaq Gains Over 150 Points; Coca-Cola Posts Upbeat Earnings U.S. stocks climbed Tuesday, led by the Nasdaq and tech shares. Coca-Cola beat Q3 estimates and raised guidance, while AI OKTO surged 74%.
benzinga.com Actuate Therapeutics Prices ~$11M Offering Of 30,986M Common Shares, Warrants At $0.71 Per Unit Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
benzinga.com Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics…
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesday's regular session. Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 151.31% to $1.0. The…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday's pre-market session. Lipocine (NASDAQ:LPCN) shares rose 52.38% to $3.2. The company's market cap…
benzinga.com Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket Penguin Solutions jumped 7.7% after beating Q4 revenue/EPS estimates and issuing above-consensus FY27 EPS guidance.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesday's after-market session. The market value of their outstanding shares is at $1.1 million. Neogen…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's regular session. The company's market cap stands at $18.6 million. Apimeds Pharmaceuticals (AMEX:APUS)…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares rose 23.4% to $6.07 during Friday's pre-market session. The market value of their outstanding shares is at $7.4 million. Firefly Neuroscience…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million. BioVie (NASDAQ:BIVI) stock…
benzinga.com HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
benzinga.com This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.- benzinga.com Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6 Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and announces Price Target of $6.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To Treat Children With Relapsed, Refractory Neuroblastoma Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced that elraglusib will be…
benzinga.com Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO - Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone- Patients…
benzinga.com HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
benzinga.com Actuate Therapeutics Announces FDA Clearance Of IND For Phase 1/2 Study Of Oral Elraglusib In Advanced Cancer Patients, With Focus On Metastatic Melanoma, NSCLC, Colorectal, And Pancreatic Cancers With Initiation Planned For 2H 2026 Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical useFDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on…
benzinga.com HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours? Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Actuate Announces Publication In Nature Medicine Reporting Phase 2 Data Showing Elraglusib + Chemotherapy Improves Survival By >40% In Metastatic Pancreatic Cancer Trial Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 18-month survival rate…
benzinga.com Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
benzinga.com HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $15 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACTU) with a Buy and lowers the price target from $20 to $15.- benzinga.com Actuate Therapeutics Launches Strategic Research Initiative To Combine Elraglusib With RAS Inhibitors The combination strategy is designed to simultaneously block proliferative signaling through RAS inhibition and disrupt tumor survival pathways via elraglusib's GSK-3β inhibition, potentially…
- benzinga.com Actuate Therapeutics Intends To Initiate Phase 1/2 Clinical Program To Evaluate Oral Tablet Dosage Form Of Elraglusib In Patients With Advanced Cancer Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat…
- benzinga.com Actuate Therapeutics Says New Additional And Patient Survival, Biomarker Data From Treatment With Elraglusib For Metastatic Pancreatic Cancer Featured In Oral And Poster Presentations At 2026 ASCO GI Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone Elraglusib…
benzinga.com Actuate Announces Results From Phase 1 Portion Of Phase 1/2 Clinical Study Evaluating Elraglusib As Monotherapy Or In Combination With Irinotecan, Irinotecan Plus Temozolomide, Or With Cyclophosphamide Plus Topotecan In Pediatric Patients With Refractory Malignancies Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic- benzinga.com Actuate Therapeutics' Data From Its Phase 2 Trial Of Elraglusib In Metastatic Pancreatic Cancer Selected For Presentation At 2026 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat…
- benzinga.com Actuate Therapeutics Announces Publication Of New Data In Clinical Cancer Research From A Phase II Study; Reports Phase II Results Of Elraglusib With Platinum Chemotherapy Shows Median Survival Of 18.6 Months In Refractory Salivary Gland Cancer Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β expression may help identify patientsmost likely to respond to…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $20 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $20 price target.
- benzinga.com Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.07 percent. This is a 54.55 percent increase over losses…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $20 price target.
- benzinga.com Actuate Therapeutics Advances Elraglusib As Potential Backbone Therapy For Pancreatic Cancer With Phase 2 Data Supporting Upcoming FDA And EMA Submissions Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides…